BRONCHITOL® (mannitol) inhalation powder may be appropriate for these potential patients*

Pen, Mobile Phone, Headphones, and Journal

Justin is a 19-year-old college student

Justin

Diagnosed with CF from childhood and has previously
been fairly adherent to his CF care plan. After moving into his fraternity house, he became busier with school and social events. He is interested in exploring other treatment options.

Medical history

  • BMI: 22.3
  • FEV1: 80% of predicted

Current CF care plan

  • Prescribed 6 medications including an inhaled antibiotic,
    dornase alfa, PERT, and CFTR modulator
  • Spends approximately 2 hours administering
    medications daily

Current lifestyle

  • Has a tendency to be rushed in the morning before class
  • Open to trying new treatments

PERT=pancreatic enzyme replacement therapy.

Not an actual patient. Patient symptoms will vary; individual evaluation should be
done to determine best course of therapy.

Important Safety Information

BRONCHITOL can cause bronchospasm, which can be severe in susceptible patients. Because of the risk of bronchospasm, prior to prescribing BRONCHITOL, patients must pass the BRONCHITOL Tolerance Test (BTT). The BTT must be administered under the supervision of a healthcare practitioner who can treat severe bronchospasm.

Please see Full Prescribing Information.

Billfold, Hand Sanitizer, Ponytail Holder, Lip Gloss, and Card

Meghan is a 35-year-old mom

Meghan

Meghan has effectively managed her CF throughout her life. Recently, she has had less time to manage her CF due to her children’s increasingly busy schedules. She is exploring other treatment options that may fit her schedule.

Medical history

  • BMI: 20.6
  • FEV1: 75% of predicted

Current CF care plan

  • Prescribed 7 medications including an inhaled antibiotic, dornase alfa, and CFTR modulator
  • Spends approximately
    1.5 hours administering medications daily

Current lifestyle

  • Spends most of the day out of the house with her children
  • Open to trying treatments that can be taken in the morning and evening

Not an actual patient. Patient symptoms will vary; individual evaluation should be done to
determine best course of therapy.

Important Safety
Information

BRONCHITOL is contraindicated in patients with hypersensitivity to mannitol or to any of the capsule components. BRONCHITOL is contraindicated in patients who fail to pass the BRONCHITOL Tolerance Test (BTT).

BRONCHITOL can cause bronchospasm, which can be severe in susceptible patients. Because of the risk of bronchospasm, prior to prescribing BRONCHITOL, patients must pass the BRONCHITOL Tolerance Test (BTT). The BTT must be administered under the supervision of a healthcare practitioner who can treat severe bronchospasm.

Patients who pass the BRONCHITOL tolerance test (BTT) may experience bronchospasm with add-on maintenance therapy with BRONCHITOL. Patients should premedicate with an inhaled short-acting bronchodilator prior to each administration of BRONCHITOL. If bronchospasm occurs, immediately discontinue BRONCHITOL and treat bronchospasm with an inhaled short-acting bronchodilator.

Hemoptysis can occur with BRONCHITOL use. Monitor patients with history of episodes of hemoptysis. If hemoptysis occurs, discontinue use of BRONCHITOL.

Most common adverse reactions (≥3%) include cough, hemoptysis, oropharyngeal pain, vomiting, bacteria sputum identified, pyrexia, and arthralgia.

Please see Full Prescribing Information.

Indication

BRONCHITOL® (mannitol) inhalation powder is a sugar alcohol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use BRONCHITOL only in adults who have passed the BRONCHITOL Tolerance Test.

Please see Full Prescribing Information.